Evidence map›Paper›PMID 29621332›Full record

ArticlePloS one2018

Prediction of response to medical therapy by serum soluble (pro)renin receptor levels in Graves' disease.

Yuki Mizuguchi, Satoshi Morimoto, Shihori Kimura, Noriyoshi Takano, Kaoru Yamashita, Yasufumi Seki, Kanako Bokuda, Midori Yatabe, Junichi Yatabe, Daisuke Watanabe and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Yuki MizuguchiDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Satoshi MorimotoDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.ORCID 0000-0002-2292-2319
Shihori KimuraDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Noriyoshi TakanoDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Kaoru YamashitaDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Yasufumi SekiDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Kanako BokudaDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Midori YatabeDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Junichi YatabeDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Daisuke WatanabeDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Takashi AndoDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Atsuhiro IchiharaDepartment of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Tokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antithyroid drugs are generally selected as the first-line treatment for Graves' Disease (GD); however, the existence of patients showing resistance or severe side effects to these drugs is an important issue to be solved. The (pro)renin receptor [(P)RR] is a multi-functional protein that activates the tissue renin-angiotensin system and is an essential constituent of vacuolar H+-ATPase, necessary for the autophagy-lysosome pathway. (P)RR is cleaved to soluble (s)(P)RR, which reflects the status of (P)RR expression. In this retrospective study, we aimed to investigate whether serum s(P)RR concentration can be used as a biomarker to predict the outcome of antithyroid drug treatment in GD patients. Serum s(P)RR levels were measured in 54 untreated GD patients and 47 control participants. Effects of medical treatment with antithyroid drugs on these levels were investigated in GD patients. Serum s(P)RR levels were significantly higher in patients with Graves' disease than in control subjects (P<0.005) and were significantly reduced after medical treatment for Graves' disease. High serum s(P)RR levels were associated with resistance to antithyroid drug treatment, suggesting that serum s(P)RR concentration can be used as a useful biomarker to predict the outcome of antithyroid drug treatment in these patients. Patients with Graves' disease with low body mass index showed higher levels of serum soluble (pro)renin receptor levels than those with high body mass index. In addition, in patients with Graves' disease, serum triglyceride levels were negatively correlated with serum soluble (pro)renin receptor levels. All these data indicated an association between low nutrient condition due to hyperthyroidism and increased (pro)renin receptor expression in these patients, suggesting that (pro)renin receptor expression could be increased in the process of stimulating intracellular energy production via activating autophagy function to compensate energy loss.

Indexed as

Antithyroid AgentsBiomarkersBody Mass IndexFemaleGraves DiseaseHumansHyperthyroidismMaleMiddle AgedProrenin ReceptorReceptors, Cell SurfaceRenin-Angiotensin SystemRetrospective StudiesTriglyceridesVacuolar Proton-Translocating ATPasesAntithyroid AgentsATP6AP2 protein, humanBiomarkersProrenin ReceptorReceptors, Cell SurfaceTriglyceridesVacuolar Proton-Translocating ATPases

Identifiers

PMID29621332
PMCPMC5886569
OpenAlexW2795636752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.